CeeTox Acquires Former ADMETRx Assets
Posted Wednesday, May 19, 2010
KALAMAZOO, Michigan, May 19, 2010 –CeeTox recently completed a transaction in which it purchased certain assets formerly owned by ADMETRx Inc. This asset purchase increases CeeTox’ existing ADME capabilities and is yet another step in its strategy to expand its range of in vitro service offerings.
Dr. Phil Burton, former cofounder, CEO, and Chief Scientific Officer of ADMETRx, has joined CeeTox as Director of ADME Services. In addition, many other former ADMETRx scientists have joined CeeTox to augment its scientific staff.
“We are pleased to have Phil on board as we continue to build a powerful CRO specialized in delivering all of the in vitro capabilities required by regulation or standard practice. We are designing our company with a single minded focus – to serve the needs of our clients with outstanding science, service, flexibility, and availability,” stated CeeTox President, Tim Mitchell.
CeeTox specializes in the development of new cutting edge in vitro assays and the deployment of validated in vitro models, each designed to identify and accurately predict in vivo toxicity. The company offers individual assays and assay panels specific to the needs of the personal care, cosmetic, pharmaceutical, chemical and medical device industries. Its assays comply with the applicable requirements of GLP, OECD, REACH, US EPA and the EU Cosmetics Directive.
For more information, contact Jean Harden, Product Manager for CeeTox, at +1-269-372-8711 or jharden@ceetox.com.